PERIPHERAL T-CELL LYMPHOMA (PTCL)
Clinical trials for PERIPHERAL T-CELL LYMPHOMA (PTCL) explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA (PTCL) trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA (PTCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a smart immune cell with a kill switch beat tough lymphomas?
⭐️ CURE ⭐️ Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA (PTCL)
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
Genetic blueprint guides new lymphoma cocktail
Disease control Not yet recruitingThis trial tests whether adding targeted drugs (azacitidine or decitabine plus selinexor) to standard chemotherapy improves outcomes for people newly diagnosed with peripheral T-cell lymphoma. Participants are assigned treatment based on their tumor's genetic profile. The study f…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA (PTCL)
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC